TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04147962

Intervention type: DEVICE
Intervention: intense pulsed light (usual practice)
Description: collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
Study: NCT02057536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm A Directed exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Study: NCT04501094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (M7824)
Description: 1200 mg administered intravenous (IV) every two weeks
Study: NCT01997723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable monitoring
Description: A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: One attended diagnostic sleep study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home portable monitoring
Description: Portable monitoring with WP200 device - applied by participants once at home.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laboratory portable monitoring
Description: Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
Study: NCT01544517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)
Description: amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)
Description: amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
Study: NCT04648007

Intervention type: DIAGNOSTIC_TEST
Intervention: Kaihani Score
Description: Assessment of neuromodulatory chemicals in peripheral blood plasma samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Kaihani Score
Description: Assessment of neuromodulatory chemicals in peripheral blood plasma samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Kaihani Score
Description: Assessment of neuromodulatory chemicals in peripheral blood plasma samples.
Study: NCT04709224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Long-Acting Injectable
Description: Lumateperone Long-Acting Injectable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone Long-Acting Injectable
Description: Lumateperone Long-Acting Injectable
Study: NCT02819869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin and Metformin use
Study: NCT01768767

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine/Lithium
Study: NCT03352310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous umbilical cord blood (UCB)
Description: autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard care
Description: standard care procedure to the newborn infants presence of HIE and/or anemia
Study: NCT00801320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor collection
Description: Tumor collected at the time of planned surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor collection
Description: Tumor collected at the time of planned surgery
Study: NCT02754154

Intervention type: DRUG
Intervention: Warfarin

Intervention type: DRUG
Intervention: Apixaban

Intervention type: DRUG
Intervention: Dabigatran

Intervention type: DRUG
Intervention: Rivaroxaban
Study: NCT04737928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: latanoprost 0.05%(one drop, once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafluprost
Description: tafluprost 0.015% (one drop, once daily)
Study: NCT03401736

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation
Description: Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The impact of Midazolam on the diversity of intestinal microbiota.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The impact of dexmedetomidine on the diversity of intestinal microbiota.
Study: NCT03675620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BFR
Description: Delfi's Personalized Tourniquet System for Blood Flow Restriction will be used with leg extension and leg press exercises. Bilateral thigh cuffs will be applied to the participants and occlusion pressure will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each participant will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between exercises. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation
Description: The control group will perform perform 4 sets of leg extensions and leg press (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
Study: NCT02149719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Desensitisation using boiled peanut

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Desensitisation using boiled peanut (deferred start)
Study: NCT00420589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taranabant
Description: taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo capsules once daily. Treatment for 52 weeks
Study: NCT03489265

Intervention type: DRUG
Group type: OTHER
Intervention: Eluxadoline 100 mg
Description: 100 mg capsule-shaped tablet by mouth taken twice per day

Intervention type: DRUG
Group type: OTHER
Intervention: Eluxadoline 100 mg
Description: 100 mg capsule-shaped tablet by mouth taken twice per day

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching capsule-shaped placebo tablets taken by mouth twice per day
Study: NCT03235804

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein, honey and yogurt.
Description: Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
Study: NCT03489265

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Matching capsule-shaped placebo tablets taken by mouth twice per day
Study: NCT02516176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill training
Description: Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
Study: NCT06228807

Intervention type: COMBINATION_PRODUCT
Intervention: The study involved a comparison of clinical characteristics, medical history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes between two groups.
Description: Differences in clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic findings, coronary microvascular function using caIMR and clinical outcomes were assessed between the two groups to identify potential risk factors. Subsequently, the incidence of clinical outcomes and mortality was compared. Univariate logistic regression and multivariate logistic regression analyses, adjusted for significant risk factors, were conducted to identify independent predictive factors. Finally, a Receiver Operating Characteristic (ROC) curve was generated, and the area under the curve was evaluated to assess the predictive accuracy of the regression model.

Intervention type: COMBINATION_PRODUCT
Intervention: The study involved a comparison of clinical characteristics, medical history, laboratory biomarkers, echocardiographic measurements, angiographic findings, and clinical outcomes between two groups.
Description: Differences in clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic findings, coronary microvascular function using caIMR and clinical outcomes were assessed between the two groups to identify potential risk factors. Subsequently, the incidence of clinical outcomes and mortality was compared. Univariate logistic regression and multivariate logistic regression analyses, adjusted for significant risk factors, were conducted to identify independent predictive factors. Finally, a Receiver Operating Characteristic (ROC) curve was generated, and the area under the curve was evaluated to assess the predictive accuracy of the regression model.
Study: NCT02392156

Intervention type: BIOLOGICAL
Intervention: rFVIIIFc
Description: As described in the treatment arm

Intervention type: BIOLOGICAL
Intervention: rFVIIIFc
Description: As described in the treatment arm

Intervention type: BIOLOGICAL
Intervention: rFIXFc
Description: As described in the treatment arm

Intervention type: BIOLOGICAL
Intervention: rFIXFc
Description: As described in the treatment arm

Intervention type: DRUG
Intervention: non-Fc FVIII replacement products
Description: Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options

Intervention type: DRUG
Intervention: non-Fc FIX replacement products
Description: Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
Study: NCT02870270

Intervention type: OTHER
Intervention: Cancer treatment
Description: Patients undergoing treatment for cancer in the head and neck region
Study: NCT02750709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
Study: NCT04145440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR202
Description: Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR202
Description: Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
Study: NCT04164641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic
Description: Physical therapy evaluation (range of motion, strength, mobility, scale). Noraxon based gait assessment on treadmill while barefoot and with instrumented inner soles. Over ground walking assessment (with wireless instrumented inner soles, observational gait analysis while climbing stairs, ramps, curbs). Noraxon gait assessment and walking on treadmill will be video recorded for assessment. Standard measure of functionality and 6 minute walk test will be conducted. Patient will be fitted with corrective orthotics, based on usual care. Physical therapy re-evaluation. Noraxon based gait assessment and foot assessment (any areas of irritation, callus formation, swelling, ulcer formation, and gait mobility irregularities will be monitored and reassessed) throughout the study.
Study: NCT04006743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The swaddling group
Description: The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The expressed breast milk group
Description: In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
Study: NCT00603395

Intervention type: DEVICE
Group type: OTHER
Intervention: ReCap Total Hip Resurfacing System
Description: This is a hip resurfacing system.
Study: NCT03184012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuSmile Zirconia crowns by NuSmile company
Description: anterior carious teeth restored with Zirconia crowns
Study: NCT04006743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The facilitated tucking group
Description: Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The swaddling and expressed breast milk group
Description: Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
Study: NCT06192420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel®
Description: 3g of gel three times daily for 7days (+1 day visit window)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium gel 1%
Description: 3g of gel three times daily for 7days (+1 day visit window)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g of gel three times daily for 7days (+1 day visit window)
Study: NCT04006743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The facilitated tucking and expressed breast milk group
Description: Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
Study: NCT02415114

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega Q Plus Resveratrol (with 50mg CoQ10)
Description: Omega Q Plus Resveratrol (with 50mg CoQ10)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega Q Plus Resveratrol (with 50mg CoQ10)
Description: Omega Q Plus Resveratrol (with 50mg CoQ10)
Study: NCT01189760

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA 24 U
Description: 24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
Study: NCT03184012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Composite resin strip crowns by 3M company
Description: anterior carious teeth restored with Strip crowns
Study: NCT01228227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATORVASTATIN 80 mg
Description: reload of Atorvastatin 80 mg before the procedure
Study: NCT01189760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 44 U
Description: 44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart

Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
Study: NCT02750709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg Tablet High Compritol
Description: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg Tablet High Compritol
Description: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg Tablet High Compritol
Description: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg Tablet High Compritol
Description: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg Tablet High Compritol
Description: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone 10 mg Tablet High Compritol
Description: A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orfadin
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orfadin
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orfadin
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orfadin
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orfadin
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orfadin
Description: A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
Study: NCT03588065

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FMS
Description: The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FMS
Description: The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception
Study: NCT01228227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROSUVASTATIN 40 mg
Description: reload of rosuvastatin 40 mg before the procedure